A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Odiparcil (Primary)
- Indications Mucopolysaccharidosis VI
- Focus Adverse reactions
- Acronyms iMProveS trial
- Sponsors Inventiva Pharma
- 13 Apr 2018 According to an Inventiva Pharma media release, results from this trial are expected in the first half of 2019.
- 11 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Mar 2020.
- 11 Apr 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Aug 2019.